Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 12/20 | 0.50 |
| ▸ | BRS3 | P32247 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | USP1 | O94782 | 3/20 | 0.34 |
| ▸ | WDR48 | Q8TAF3 | 3/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9969400 | 0.89 | NOTUM (0.54) | NOTUMBRS3CYP19A1KEAP1USP1 | |
| SCHEMBL19683363 | 0.86 | CYP19A1 (0.53) | NOTUMBRS3CYP19A1BCHE | |
| SCHEMBL14567879 | 0.83 | CYP19A1 (0.63) | NOTUMBRS3CYP19A1BCHE | |
| SCHEMBL19683458 | 0.83 | CYP19A1 (0.50) | NOTUMBRS3CYP19A1BCHE | |
| SCHEMBL13527241 | 0.82 | CYP19A1 (0.61) | NOTUMBRS3CYP19A1BCHE | |
| SCHEMBL4966052 | 0.80 | NOTUM (0.50) | NOTUMBRS3CYP19A1KEAP1 | |
| SCHEMBL12776174 | 0.80 | NOTUM (0.58) | NOTUMBRS3CYP19A1KEAP1USP1 | |
| SCHEMBL21156935 | 0.79 | NOTUM (0.54) | NOTUMBRS3CYP19A1KEAP1USP1 | |
| SCHEMBL6853891 | 0.78 | NOTUM (0.51) | NOTUMBRS3CYP19A1KEAP1 | |
| SCHEMBL4970815 | 0.78 | NOTUM (0.51) | NOTUMBRS3CYP19A1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-07-11 | — | — | US | disclosed |
| US-20170349621-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2017-12-07 | — | — | US | disclosed |
| US-20170349621-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2017-12-07 | — | — | US | disclosed |
| US-20160152654-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2016-06-02 | — | — | US | disclosed |
| US-9085600-B2 | Triazole compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140094422-A1 | Triazole Compounds and Methods of Making and Using the Same | SILICON VALLEY BANK | 2014-04-03 | — | — | US | disclosed |
| US-8470985-B2 | Triazole compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20100016955-A1 | Triazole compounds and methods of making and using the same | BioVersys AG (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016955-A1 | Triazole compounds and methods of making and using the same | IL33, PROKR1, VIP | NOTUM 2600/4885BRS3 877/4885CYP19A1 2296/4885 |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | NOTUM 2701/4885BRS3 1622/4885CYP19A1 1310/4885 |
| US-20170349621-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | NOTUM 3719/4885BRS3 794/4885CYP19A1 709/4885 |
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | NOTUM 3719/4885BRS3 794/4885CYP19A1 709/4885 |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | VIP, PROKR1, PGC | NOTUM 1965/4885BRS3 2368/4885CYP19A1 3145/4885 |
| US-20140094422-A1 | Triazole Compounds and Methods of Making and Using the Same | PROKR1, ARG1, ARG2 | NOTUM 3719/4885BRS3 794/4885CYP19A1 709/4885 |
| US-20160152654-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | NOTUM 3719/4885BRS3 794/4885CYP19A1 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.